Ameriprise’s Evolent Health EVH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $931K | Buy |
+171,751
| New | +$658K | ﹤0.01% | 3434 |
|
|
2026
Q1 | – | Sell |
-532,133
| Closed | -$2.13M | – | 4115 |
|
|
2025
Q4 | $2.13M | Buy |
532,133
+27,971
| +6% | +$155K | ﹤0.01% | 2961 |
|
|
2025
Q3 | $4.27M | Buy |
504,162
+217,762
| +76% | +$2.11M | ﹤0.01% | 2548 |
|
|
2025
Q2 | $3.22M | Buy |
286,400
+14,176
| +5% | +$130K | ﹤0.01% | 2686 |
|
|
2025
Q1 | $2.58M | Buy |
272,224
+41,187
| +18% | +$416K | ﹤0.01% | 2763 |
|
|
2024
Q4 | $2.6M | Sell |
231,037
-37,312
| -14% | -$656K | ﹤0.01% | 2776 |
|
|
2024
Q3 | $7.59M | Sell |
268,349
-5,015
| -2% | -$129K | ﹤0.01% | 2047 |
|
|
2024
Q2 | $5.23M | Sell |
273,364
-8,754
| -3% | -$224K | ﹤0.01% | 2268 |
|
|
2024
Q1 | $9.25M | Buy |
282,118
+34,828
| +14% | +$1.11M | ﹤0.01% | 1858 |
|
|
2023
Q4 | $8.17M | Buy |
247,290
+48,281
| +24% | +$1.37M | ﹤0.01% | 1951 |
|
|
2023
Q3 | $5.42M | Sell |
199,009
-90,169
| -31% | -$2.51M | ﹤0.01% | 2216 |
|
|
2023
Q2 | $8.76M | Sell |
289,178
-10,205
| -3% | -$330K | ﹤0.01% | 1884 |
|
|
2023
Q1 | $9.71M | Buy |
299,383
+57,470
| +24% | +$1.82M | ﹤0.01% | 1802 |
|
|
2022
Q4 | $6.79M | Buy |
241,913
+23,148
| +11% | +$664K | ﹤0.01% | 2075 |
|
|
2022
Q3 | $7.86M | Buy |
218,765
+75,749
| +53% | +$2.67M | ﹤0.01% | 1885 |
|
|
2022
Q2 | $4.39M | Sell |
143,016
-29,589
| -17% | -$862K | ﹤0.01% | 2376 |
|
|
2022
Q1 | $5.57M | Buy |
172,605
+22,983
| +15% | +$602K | ﹤0.01% | 2352 |
|
|
2021
Q4 | $4.14M | Sell |
149,622
-4,232
| -3% | -$121K | ﹤0.01% | 2596 |
|
|
2021
Q3 | $4.77M | Sell |
153,854
-33,633
| -18% | -$807K | ﹤0.01% | 2421 |
|
|
2021
Q2 | $3.96M | Sell |
187,487
-14,546
| -7% | -$291K | ﹤0.01% | 2606 |
|
|
2021
Q1 | $4.08M | Buy |
202,033
+22,496
| +13% | +$428K | ﹤0.01% | 2509 |
|
|
2020
Q4 | $2.88M | Buy |
179,537
+58,024
| +48% | +$767K | ﹤0.01% | 2611 |
|
|
2020
Q3 | $1.51M | Sell |
121,513
-38,743
| -24% | -$456K | ﹤0.01% | 2805 |
|
|
2020
Q2 | $1.14M | Sell |
160,256
-64,028
| -29% | -$429K | ﹤0.01% | 2872 |
|
|
2020
Q1 | $1.22M | Buy |
224,284
+32,066
| +17% | +$286K | ﹤0.01% | 2735 |
|
|
2019
Q4 | $1.74M | Buy |
192,218
+10,163
| +6% | +$82.6K | ﹤0.01% | 2796 |
|
|
2019
Q3 | $1.31M | Sell |
182,055
-132,588
| -42% | -$951K | ﹤0.01% | 2897 |
|
|
2019
Q2 | $2.5M | Sell |
314,643
-156,104
| -33% | -$1.85M | ﹤0.01% | 2610 |
|
|
2019
Q1 | $5.92M | Sell |
470,747
-758,511
| -62% | -$12M | ﹤0.01% | 2111 |
|
|
2018
Q4 | $24.5M | Sell |
1,229,258
-537,462
| -30% | -$12.4M | 0.01% | 939 |
|
|
2018
Q3 | $50.2M | Buy |
1,766,720
+645,616
| +58% | +$15.4M | 0.02% | 752 |
|
|
2018
Q2 | $23.6M | Buy |
+1,121,104
| New | +$21.2M | 0.01% | 1058 |
|
|
2018
Q1 | – | Sell |
-98,802
| Closed | -$1.22M | – | 3640 |
|
|
2017
Q4 | $1.22M | Buy |
98,802
+12,798
| +15% | +$180K | ﹤0.01% | 2897 |
|
|
2017
Q3 | $1.53M | Sell |
86,004
-82,375
| -49% | -$1.7M | ﹤0.01% | 2750 |
|
|
2017
Q2 | $4.27M | Buy |
168,379
+93,133
| +124% | +$2.24M | ﹤0.01% | 2185 |
|
|
2017
Q1 | $1.68M | Sell |
75,246
-1,330
| -2% | -$25.5K | ﹤0.01% | 2664 |
|
|
2016
Q4 | $1.13M | Buy |
+76,576
| New | +$1.51M | ﹤0.01% | 2911 |
|
|
2016
Q3 | – | Sell |
-81,501
| Closed | -$1.56M | – | 3797 |
|
|
2016
Q2 | $1.56M | Buy |
+81,501
| New | +$1.12M | ﹤0.01% | 2648 |
|
Other funds holding EVH
CCM
RF
EC
Ameriprise's EVH Position: Q2 2026 in Review
Ameriprise opened a new position in Evolent Health (EVH) in Q2 2026: 171,751 shares worth $931K. The stake represents ﹤0.01% of the portfolio and ranks #3434 among its holdings. This is a return to the name: Ameriprise previously reported a position in EVH as recently as Q4 2025.
Ameriprise first reported a position in EVH in Q2 2016 and has held it in 38 quarters since. The position peaked at $50.2M in Q3 2018. 199 funds tracked by Wall St. Rank hold EVH as of Q2 2026.
- Ameriprise held 171,751 shares of Evolent Health worth $931K as of Q2 2026.
- Evolent Health was a new Ameriprise position in Q2 2026.
- Evolent Health made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #3434 holding.
- Ameriprise first reported a position in Evolent Health in Q2 2016 and has held it in 38 quarters since.
- Ameriprise's Evolent Health position peaked at $50.2M in Q3 2018.
- 199 funds tracked by Wall St. Rank held Evolent Health as of Q2 2026.
Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.